IC31® Tuberculosis vaccine
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, the most common agent, and Mycobacterium bovis. According to the WHO, one human is newly infected with M. tuberculosis every second. About one-third of the world's population carries the pathogen latently with the disease causing the death of more than 1.6 million people every year. This makes TB one of the most severe global health problems today.
Phase I and II studies in the field of Tuberculosis
Valneva is collaborating with the Statens Serum Institut (SSI). Three clinical vaccine candidates, all formulated with Valneva’s IC31®
adjuvant, are being assessed in human clinical trials (Phase I and II), supported by the European and Developing Countries Clinical Trials Partnership (EDCTP), the Tuberculosis Vaccine Initiative (TBVI), and the South African Tuberculosis Vaccine Initiative SATVI (Phase II) and Grand Challenges in Global Health in partnership with Aeras and SATVI (Phase I).
Under a strategic alliance agreement signed in 2007, Novartis received a license for the use of IC31® in selected new vaccines. Following investigation of IC31® in influenza vaccines, Novartis has initiated another Phase I clinical trial, combining an additional undisclosed vaccine candidate with the IC31® adjuvant in 2011. In 2015, the programs under the strategic alliance agreement have transitioned to GSK.
Furthermore, Valneva maintains research collaborations with various partners to evaluate IC31® in new vaccine formulations and additional collaborations have been initiated in the field of cancer.